Neurological Disorders Summit

July 06-08, 2015
DoubleTree by Hilton Hotel San Francisco Airport
San Francisco, USA

Improvising Advanced Tools and Techniques for Better Therapeutics

Sponsors

BMI
Biomedical Imaging

PLAXGEN
Particles Innovation for Longer Life
Day 1 @ Sierra A
Monday July 6, 2015

Inauguration NDS-2015 .......................... 09:00-9:30

Keynote Session

09:30-09:55.........
Biologically based genomic therapy for brain reward deficiency syndrome: are we going to the promised land?
Kenneth Blum, University of Florida, USA

09:55-10:20.........
Recent progresses on neuroimaging with ultra-high field MRI
Zang-Hee Cho, Seoul National University, South Korea

10:20-10:45.........
Intranasal small molecules, proteins, oligonucleotides and stem cells bypass the blood-brain barrier and target the brain to treat Alzheimer’s, Parkinson’s, stroke, brain tumors, MS and other brain disorders
William H. Frey II, University of Minnesota, USA

10:45-11:10.........
Genomics view of neurodegenerative disease
Shoji Tsuji, The University of Tokyo Hospital, Japan

Coffee Break ............... 11:10-11:25

Break Out 1 @ Sierra A A

Speaker Session

• Diagnostics of neurological disorders: Symptomatology, pathophysiology and etiology
• Diagnostics of neurological disorders: Neuroimaging and laboratory studies
• Parkinson’s disease and other movement disorders

Session Chairs
Joel N. Buxbaum, The Scripps Research Institute, USA
Wagner Zago, Prothena Biosciences, USA

11:25-11:45........
Gene-environment interactions, experience-dependent plasticity and therapeutic targets for neurological disease
Anthony J. Hannan, University of Melbourne, Australia

11:45-12:05........
Transferrin and the nervous system: friend or foe?
Joel N. Buxbaum, The Scripps Research Institute, USA

12:05-12:25........
Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor inhibit ferrous iron influx via divalent metal transporter 1 and iron regulatory protein 1 regulation in ventral mesencephalic neurons
Ning Song, Medical College of Qingdao University, China

12:25-12:45........
Dopamine turnover in the nigrostriatal system of MPTP-treated mice at the presymptomatic and early symptomatic stages of Parkinsonism
Michael Ugrumov, Institute of Developmental Biology RAS, Russia

12:45-13:05........
Genomics-based bioinformatics analysis of Parkinson’s disease
Li M. Fu, AHMC Healthcare, USA

13:05-13:25........
The death of human cortical neurons due to exposure to exogenous Aβ oligomers prevented by NPS 2143, a selective antagonist of the calcium-sensing receptor
Ilaria Dal Pra, University of Verona, Italy
### Lunch Break & Networking  13:25-14:10

| 14:10-14:30 | Synuclein immunotherapy for Parkinson’s disease and other synucleinopathies  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Wagner Zago, Prothena Biosciences, USA</td>
</tr>
</tbody>
</table>
| 14:30-14:50 | Analysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson’s disease  
|             | Soliman Khatib, Tel-Hai College, Israel                                        |
| 14:50-15:10 | Role of GRKS in L-DOPA-induced dysthesia                                      |
|             | Eugenia V Gurevich, Vanderbilt University Medical Center, USA                  |
| 15:10-15:30 | Cytokine-dependent synaptopathy at the basis of disability progression in multiple sclerosis  
|             | Silvia Rossi, Fondazione Istituto Neurologico Carlo Besta, Italy               |
| 15:30-15:50 | Extrapyramidal syndrome: needs more attention                                 |
|             | S. Mohammad Moosavi, Mazandaran University of Medical Sciences, Iran           |
| 15:50-16:10 | A case of anoxic brain damage - an anthropological perspective                |
|             | Elisabeth L’ Orange Furst, University of Oslo, Norway                          |

### Coffee Break  16:10-16:30

| 16:30-16:50 | Ganglioside GM1 deficiency as a cause of Parkinson’s disease                  |
|             | John Forsayeth, University of California San Francisco, USA                   |
| 16:50-17:10 | Saposin C and the glucocerebrosidase/alpha-synuclein connection in Parkinson’s disease  
|             | James M. Gruschus, National Institutes of Health, USA                         |
| 17:10-17:30 | Tremor in Parkinson’s patients using deep brain stimulation and cueing       |
|             | Tjitske Heida T, University of Twente, The Netherlands                        |
| 17:30-17:50 | Progress in development of anti-Parkinson drug with unique specificity       |
|             | Judit Ovadi, Hungarian Academy of Sciences, Hungary                           |
| 17:50-18:10 | Mitochondrial fission at the nerve terminal in susceptible neurons           |
|             | Ken Nakamura, University of California, USA                                  |
| 18:10-18:30 | Sulfanylphthalimides: a novel class of dual-acting compounds for the treatment of Parkinson’s and Alzheimer’s disease  
|             | Mietha M. Van der Walt, North-West University, South Africa                  |
| 18:30-18:50 | Clinical features and diagnosis of chronic traumatic encephalopathy         |
|             | Philip Homes Montenigra, Boston University School of Medicine, USA            |

### Break Out 2 @ Sierra B

### Speaker Session

**Alzheimer’s disease, dementia, mild cognitive impairment, and behavioral diseases**

<table>
<thead>
<tr>
<th>Joy L. Taylor</th>
<th>Stanford University School of Medicine, USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martine Simard</td>
<td>University Laval, Canada</td>
</tr>
<tr>
<td>Troy T. Rohn</td>
<td>Boise State University, USA</td>
</tr>
</tbody>
</table>

### Session Chairs

- Martine Simard, University Laval, Canada  
- Troy T. Rohn, Boise State University, USA

**The role of SNCA gene in Lewy body spectrum disorders: genetic variations, expression and splicing**

| Ornit Chiba-Falek | Duke University School of Medicine, USA                                   |

**11:25-11:45**
11:45-12:05 Pyrethroid pesticide in the pathophysiology of Alzheimer’s disease: role of EGFR signaling
Sanghamitra Bandyopadhyay, CSIR-Indian Institute of Toxicology Research, India

12:05-12:25 The role of sirtuins in Alzheimer’s disease: a new therapeutic target
Yıldız Dinçer, Istanbul University, Turkey

12:25-12:45 PACAP and Alzheimer’s disease
Peng Cheng Ha, Dignity Health St Joseph’s Hospital, USA

12:45-13:05 Cognitive rehabilitation in Alzheimer’s disease: concepts, evidence and challenges
Martine Simard, University Laval, Canada

Joy L. Taylor, Stanford University School of Medicine, USA

Lunch Break & Networking  13:25-14:10

14:10-14:30 Modulators of proteasome function and β-Amyloid toxicity
Wail M. Hassan, University of Wisconsin, USA

14:30-14:50 Granulovacuolar degeneration and tau fibrillary pathology
Christoph Köhler, University of Cologne, Germany

14:50-15:10 Neurotensin and Alzheimer’s disease: therapeutic potential of NTS1 agonists
Saobo Lei, University of North Dakota, USA

15:10-15:30 Proteolytic cleavage of apolipoprotein E4 as the keystone for the heightened risk associated with Alzheimer’s disease
Troy T. Rohn, Boise State University, USA

15:30-15:50 A potential function of secreted exosomes in sequestering Alzheimer’s amyloid-β peptide
Yasuyuki Igarashi, Hokkaido University, Japan

15:50-16:10 Insulin degrading enzyme and Alzheimer disease and Type 2 diabetes
Hugo Gutiérrez-Hermosillo, Hospital Aranda de la Parra, México

Coffee Break  16:10-16:30

16:30-16:50 Rationale and discussion into parallels on depression and Alzheimer’s disease and different genomic vulnerability leading to therapeutic utilities
Roberto Rodrigues, University of Texas San Antonio, USA

16:50-17:10 Effects of natural Cerebrolysin on the early intervention of Alzheimer’s disease and its molecular mechanism
Feijuan Huang, First Affiliated Hospital of Shenzhen University, China

17:10-17:30 Testing a structural equation model of language-based cognitive fitness with longitudinal data
Elizabeth Moxley-Paquette, Wasdell Academy Ontario, Canada

17:30-17:50 Using the MMSE as a cognitive screener among Turkish and Moroccan migrants
Lennaert A.R. Zwart, Slotervaart Hospital, The Netherlands

17:50-18:10 Prevalence of domain-specific cognitive impairment in patients with COPD
Fiona Cleutjens, Centre of Expertise for Chronic Organ Failure, The Netherlands
Beta adrenergic signaling in Down syndrome and Alzheimer’s disease
Ahmad Salehi, Stanford Medical School, USA

Multiscale genomic approach and Big Data analysis support a shared etiology between Type 2 Diabetes and Alzheimer’s disease
Giulio Maria Pasinetti, Icahn School of Medicine at Mount Sinai, USA

Imaging neurotransmission in the live human brain
Rajendra D. Badgaiyan, University of Minnesota, USA

Biomarkers- directed strategies to prevent, early diagnose and treat autism
Afaf El-Ansary, King Saud University, Saudi Arabia

P - 01
MTRNR2L12: a candidate blood marker of early Alzheimer’s disease-like dementia
Miroslaw Bik-Multanowski, Jagiellonian University Medical College, Poland

P - 02
The contributions of game therapy in motor performance of individual with cerebral palsy
Thiago Da Silva Dias, MCPHS University, USA

P - 03
Analysis of iPSC-derived dopaminergic neuron susceptibility to influenza and excitotoxicity in non-affective psychosis
Jamileh Ahmed, University of South Florida, USA

P - 04
The effects of mirror therapy on the gait of subacute stroke patients: a randomized controlled trial
Myoung-kwon Kim, Daegu University, Republic of Korea

P - 05
Which type of cane is the most efficient, based on oxygen consumption and balance capacity, in chronic stroke patients?
Jung-Wan Koo, The Catholic University of Korea, Republic of Korea

P - 06
The effect of smartphone-based speed-interactive treadmill exercise using body motion tracking technology on gait in stroke patients
Changho Song, Sahmyook University, South Korea

P - 07
HIV-1 Vpr disrupts axonal transport through induction of α-Synuclein
Ying Wang, Temple University, USA

P - 08
Vitamin D immunomodulatory potential in multiple sclerosis
Georgi Slavov, Medical University, Bulgaria

P - 09
Memory-enhancing and neuroprotective actions of N-palmitoyl serotonin in scopolamine-induced amnesia mice
Mee Ree Kim, Chungnam National University, Korea

P - 10
Transcranial Direct Current Stimulation (tDCS) therapy for major depressive disorder in HIV population: a safe, effective noninvasive promising treatment as compared to conventional antidepressant therapy
Satneet Singh, Cooper University Hospital, New Jersey and Mariyah Z. Hussain, Foundation University Medical College, Pakistan
Increasing self-awareness in students with autism
Christine K Duff, University of Central Florida, USA

The impact of sleep quality on cognitive functioning in veterans “with complex medical problems”
Michelle Madore, Stanford University School of Medicine, USA

Induction of spinal GluN2B-dependent LTP via BDNF contributes to the development of neuropathic pain
Xu Ding, Beijing Children’s Hospital, China

Genetics and migraine: study on the relationship between COMT and migraine
Svetlana Kantorovich, Proove Biosciences, USA

Genetics and fibromyalgia: study on the relationship between 5HT2a and fibromyalgia
Svetlana Kantorovich, Proove Biosciences, USA

Genetics and insomnia: study on the role of DAT1 in risk of insomnia
Svetlana Kantorovich, Proove Biosciences, USA

Bifunctional modulators of Aβ aggregation as potential agents for Alzheimer’s disease therapy
Ming-Kuan Hu, National Defense Medical Center, Taiwan

Restraint stress-induced neuronal loss involves brain glutathione system and resveratrol has reversed this effect in rat brain
Sampath Kumar Madhyastha, Kasturba Medical College, India

Rhinocerebral mucormycosis with top of basilar artery syndrome
N. S. Sampath Kumar, Narayana Medical college and Hospital, India

Effect of Tai Chi Chuan on balance in women with multiple sclerosis
Mohammadali Hosseini, University of Social Welfare and Rehabilitation Sciences, Iran

Association of multidrug resistance protein 1 (MRP1) gene polymorphism in malignant glioma in north Indian population under Temozolomide based chemo-radiation therapy.
Srinivasan Munisamy, All India Institute of Medical Sciences, India

Eosinophilic meningitis in a child with thalamic infarct
Suchetha Rao, Manipal University, India

On base of space time theory, neurological disorders are the results of chaos in neurons released electromagnetism wavelengths as the consequence of abnormalities in brain metabolism
Mojtaba Omid, Istanbul University Medical School, Turkey

Electroencephalographic characteristics of Iranian schizophrenia patients
Irman Chaychi, Mashhad University of Medical Sciences, Iran

The effects of a six-week motorized aquatic treadmill exercise program on cardiorespiratory fitness and walking endurance in subacute stroke patients
Eun Young Han, Jeju National University, South Korea

A research on the assessment of patients with schizophrenia aggressive by using quantum resonance spectrometer
Jianguo Shi, Xi’an Mental Health Center, China

Unemployment is one of risk factors of depression disorder
Yan Zhang, Xi’an Mental Health Center, China
A computational model of autism disorder: towards developing assistive technology to improve life’s quality
Reyes Juárez-Ramírez, Autonomous University of Baja California, México

Development of novel platelet adhesion inhibitor and its implication to stroke
Lin Zhang, Ministry of Education, Tianjin University, China

Break Out 1 @ Sierra A

Speaker Session

- Neuromuscular disorders and peripheral neuropathies
- Autism and neurodevelopmental disorders
- Biomarkers and disease mechanisms in neurological disorders

Session Chairs
Alysson Muotri, University of California San Diego, USA
Shanmugavel Madasamy, Plaxgen Inc., USA

11:00-11:20
Trends with corticosteroid use in males with Duchenne muscular dystrophy born 1982-2001
Deborah J. Fox, New York State Department of Health, USA

11:20-11:40
A human model: changing the focus on autism research
Alysson Muotri, University of California San Diego, USA

11:40-12:00
Recognition of homocysteine as a risk factor for peripheral neuropathy in clinical practice
Jin J Luo, Temple University, USA

12:00-12:20
Spasticity management, update in children and adult
Yasser Awaad, University of Michigan, USA

12:20-12:40
Pathobiologic alterations in preclinical Alzheimer’s disease
Howard Federoff, Georgetown University, USA

12:40-13:00
Neuroinflammation and chronic neurodegeneration after traumatic brain injury: new therapeutic target
Alan I. Faden, University of Maryland School of Medicine, USA

13:00-13:20
Oxidative stress in Rett syndrome: cause or consequence?
Joussef Hayek, Azienda Ospedaliera Universitaria Senese, Italy

13:20-14:05
Lunch Break & Networking

14:05-14:25
Examining the implementation of a social engagement intervention for children with autism in public school settings
Jill Locke, University of Pennsylvania, USA

14:25-14:45
Evidence-based practices for children with autism spectrum disorders and deafness
Stacey Jones Bock and Christina Borders, Illinois State University, USA

14:45-15:05
Teaching persistence in social initiations to children with autism: a portable video modeling intervention
Denise Grosberg, Rady Children’s Hospital, USA

15:05-15:25
Teaching advance movement exploration skills in water to children with autism spectrum disorders
Mehmet Yanardag, Anadolu University, Turkey

15:25-15:45
Treatment of autism with low-dose phenytoin
Philip Bird, Gosforth Clinic, Australia

15:45-16:05
Somatosensory evoked potentials in children with autism?
Hanan Galal Azouz, Alexandria University, Egypt
Break Out 2 @ Sierra B

Speaker Session

- Neurodegenerative diseases
- Therapeutic options and treatment
- Prevention and treatment strategies

Session Chairs

Ta Yuan Chang, Geisel School of Medicine Dartmouth, USA
Othman Ghribi, University of North Dakota, USA

11:00-11:20
Molecular elucidation and engineering of stem cell fate decisions
David Schaffer, University of California at Berkeley, USA

11:20-11:40
Attenuation of Aβ25−35-induced parallel autophagic and apoptotic cell death by Gypenoside XVII through the estrogen receptor-dependent activation of Nrf2/ARE pathways
Ming Wang, Chinese Academy of Medical Sciences, China

11:40-12:00
A role for inflammation in the pathogenesis of Lyme neuroborreliosis
Geeta Ramesh, Tulane National Primate Research Center, USA

12:00-12:20
ACAT1/SOAT1 as a therapeutic target for Alzheimer’s and other related neurodegenerative diseases
Ta Yuan Chang, Geisel School of Medicine Dartmouth, USA

12:20-12:40
Use of Paroxetine as a neuroprotective therapeutic
Joseph P. Steiner, NIH/NINDS, USA

12:40-13:00
Oxysterols-multifaceted players in neurodegenerative diseases
Othman Ghribi, University of North Dakota, USA

13:00-13:20
NADPH oxidase activation and 4-hydroxy-2-nonenal/aquaporin-4 adducts as possible new players in oxidative neuronal damage presents in drug-resistant epilepsy
Giuseppe Valacchi, University of Ferrara, Italy

Coffee Break ...............16:05-16:25

16:25-16:45
The role of neuroinflammation in tau pathology; therapeutic perspective
Mai-Linda B. Selenica, University of South Florida, USA

16:45-17:05
Plaque array and particles targeted proteomics based identification of serum biomarkers for Alzheimer’s disease
Shanmugavel Madasamy, Plaxgen Inc, USA

17:05-17:25
Epileptic encephalopathy mutations in KCNQ2 disrupt axonal enrichment of KCNQ potassium channels and excitability in hippocampal neurons
Hee Jung Chung, University of Illinois at Urbana-Champaign, USA

17:25-17:45
β-amyloidogenic peptides protect against herpes simplex virus-1 infections
Karine Bourgade, University of Sherbrooke, Canada

17:45-18:05
Biomarkers and disease mechanisms in neurological/neurodegenerative disorders
Sadhana Sathaye, Institute of Chemical Technology, India

18:05-18:25
The use of circadian rhythm in individualising treatments in ADHD
Onur Burak Dursun, Atatürk University, Turkey

Lunch Break & Networking ...............13:20-14:05
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution/University</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:05-14:25</td>
<td>Pharmacogenetics of phase II metabolizing enzyme uridine diphosphate glucuronosyltransferase (UGT) genetic polymorphism on sodium valproate pharmacokinetics in epilepsy</td>
<td>Murali Munisamy, King Khalid University, KSA</td>
<td></td>
</tr>
<tr>
<td>14:25-14:45</td>
<td>Association of prone position with sudden unexpected death in epilepsy</td>
<td>James Tao, The University of Chicago, USA</td>
<td></td>
</tr>
<tr>
<td>14:45-15:05</td>
<td>Prevalence of drug resistant epilepsy in adults with epilepsy attending a neurology clinic of a tertiary referral hospital in Singapore</td>
<td>Paul C. Ho, National University of Singapore, Singapore</td>
<td></td>
</tr>
<tr>
<td>15:05-15:25</td>
<td>Choosing antiepilepsy drugs by seizure characteristics: a novel concept</td>
<td>Paul H McCabe, Geisinger Health System, USA</td>
<td></td>
</tr>
<tr>
<td>15:25-15:45</td>
<td>AMPA receptor antagonists for the treatment of epilepsy: a novel approach based upon auxiliary proteins</td>
<td>Jeffrey M. Witkin, Lilly Research Labs, USA</td>
<td></td>
</tr>
<tr>
<td>15:45-16:05</td>
<td>Alpha-synuclein amyloid interaction with prion protein: a putative overlap of two neurodegenerative diseases</td>
<td>Giuseppe Legname, Scuola Internazionale Superiore di Studi Avanzati, Italy</td>
<td></td>
</tr>
</tbody>
</table>

**Coffee Break** 16:05-16:25

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution/University</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:25-16:45</td>
<td>Expression of one important chaperone protein, heat shock protein 27, in neurodegenerative diseases</td>
<td>Xuekai Zhang, Beijing University of Chinese Medicine, China</td>
<td></td>
</tr>
<tr>
<td>16:45-17:05</td>
<td>Amphetamine and β-phenylethylamine cause locomotor effects through activation of an amine-gated chloride channel</td>
<td>Lucia Carvelli, University of North Dakota School of Medicine, USA</td>
<td></td>
</tr>
<tr>
<td>17:05-17:25</td>
<td>Association of serotonin transporter gene (5HTT) polymorphism and juvenile myoclonic epilepsy: a case -control study</td>
<td>Eman H Esmail, Cairo University, Egypt</td>
<td></td>
</tr>
<tr>
<td>17:25-17:45</td>
<td>Post status epilepticus treatment with the cannabinoid agonist WIN 55,212-2 prevents chronic epileptic hippocampal damage in rats</td>
<td>Roberto Di Maio, University of Pittsburgh, USA</td>
<td></td>
</tr>
<tr>
<td>17:45-18:05</td>
<td>Complex phenomenon of suicide: neurobiology and clinical aspects of the unmet public health dilemma</td>
<td>Mariyah Z. Hussain, Foundation University Medical College, Pakistan</td>
<td></td>
</tr>
<tr>
<td>18:05-18:25</td>
<td>Anti-fibrillogenic and fibril destabilizing effects of metal ions for goat brain cystatin (GBC) fibrils in vitro</td>
<td>Waseem Feeroze Bhat, Aligarh Muslim University, India</td>
<td></td>
</tr>
<tr>
<td>18:25-18:45</td>
<td>Neuropharmacological review of the nootropic herb Bacopa monnieri</td>
<td>Sebastian Aguilar, Claremont Colleges, USA</td>
<td></td>
</tr>
</tbody>
</table>

**Reception** 19:00-20:15
Day 3
Wednesday July 8, 2015
Break Out 1 @ Sierra A

Speaker Session

• Advances in stroke management • Stroke: prevention, treatment and recovery

Session Chairs

Javed Iqbal, Punjab Institute of Cardiology, Pakistan
Manish Parakh, Dr S N Medical College, India

Excitotoxic potential of adenosine signaling in the brain: novel targets for Neuroprotection?
Francisco S. Cayabyab, University of Saskatchewan, Canada

The value of adding somatosensory stimulation to mirror therapy on muscular, sensorimotor and daily function in stroke patients: a randomized, placebo-controlled study
Ching-yi Wu, Chang Gung University, Taiwan

Stroke after coronary artery bypass surgery with and without cardiopulmonary bypass
Javed Iqbal, Punjab Institute of Cardiology, Pakistan

Impact of bone fracture on stroke recovery
Hua Su, University of California, USA

Coffee Break ................10:20-10:35

10:35-10:55.............. Cost-effectiveness of Dabigatran and Rivaroxaban compared with Warfarin for stroke prevention in patients with atrial fibrillation
Ye Wang, Harvard Medical School, USA

10:55-11:15.............. C.I.M.T : theory of research in neurorehabilitation for patients with severe brain injury
Ylenia Tripovic, Centro Adelphi, Italy

11:15-11:35.............. CIMT in patients with an outcome of brain injury after stroke vs post TBI
Francesco Formenti, Centro Adelphi, Italy

11:35-11:55.............. Detection of atrial fibrillation in stroke patients
Gerben J. J. Plas, Medisch Spectrum Twente, The Netherlands

The enigma of relationship between anemia and pediatric stroke; a prospective study evaluating relationship between iron status parameters and hematologic indices with pediatric stroke
Manish Parakh, Dr S N Medical College, India

12:15-12:35.............. Atrial fibrillation is associated with disturbed glucose metabolism in patients with ischemic stroke and TIA
Elizabeth Osei, Medisch Spectrum Twente, The Netherlands

Abdelmoneim Awad, Kuwait University, Kuwait

12:55-13:15.............. Vit. D3 as a prognostic factor in cerebro vascular stroke
N. S. Sampath Kumar, Narayana Medical College and Hospital, India

Stimulation of NMDA receptors in the recovery phase after transient ischemia in rats: outcomes and mechanisms
Anat Biegon, Stony Brook University, USA

Lunch Break & Networking ..................13:35-14:30
Multiple sclerosis and CNS demyelinating disorders • Migraine and headaches • Rehabilitation, devices, and services for patients and caregivers • Case studies and ethical issues

**Workshop:**
Save your patients. Save your practice. Fill your pockets. The power of pharmacogenetics testing
Cicely Everson, American Academy of Anti-Aging Medicine, United States

09:00-09:40........
Pathological patterns in relapsing-remitting and chronic models of multiple sclerosis and the therapeutic effect of glatiramer acetate
Rina Aharoni, The Weizmann Institute of Science, Israel

09:40-10:00........
Acute pancreatitis, possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis
Hongxiu Luo, Raritan Bay Medical Center, USA

10:00-10:20........

**Coffee Break .............10:20-10:35**

10:35-10:55........
Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study
Foad Taghdiri, Tehran University of Medical Sciences, Iran

10:55-11:15........
Analytic information processing style and neurophysiological correlates: focus on migraine and cluster headache
Marzia Buonfiglio, Sapienza University of Rome, Italy

11:15-11:35........
Changing definitions of euphoria in multiple sclerosis: a short report
Amy Duncan, University of Cape Town, South Africa

11:35-11:55........
Cytokines in MS – possible targets for immune therapies
Anastasiya Trenova, Medical University -Plovdiv, Bulgaria

11:55-12:15........
BMT monitors neuropsychiatric disorders with bio-impedance units
Yakov Naisberg, National Israeli Center for Psychosocial Support of Survivors of the Holocaust and the Second Generation, Israel

12:15-12:35........
Caregiving immediately after stroke: a study of depressive symptoms in caregivers of older adults
Eeseung Byun, University of California, USA

12:35-12:55........
A new assessment for episodic memory. Episodic memory test and caregiver’s episodic memory test
T. Oliva Ortega, Hospital Regional Universitario Carlos Haya, Spain

12:55-13:15........
Collision or convergence? Beliefs and politics in neuroscience discovery, ethics, and intervention
Ben Paylor, University of British Columbia, Canada

13:15-13:35........
Impact of dopamine on T cell behavior of MS patient
Cleonice Bento, Federal University of the State of Rio de Janeiro, Brazil

**Lunch Break & Networking .................13:35-14:30**
We wish to meet you again at NDS-2016.